Lonza Group (LZAGY)
(Delayed Data from OTC)
$62.52 USD
-1.45 (-2.27%)
Updated Sep 20, 2024 03:59 PM ET
1-Strong Buy of 5 1
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Lonza Group Ag [LZAGY]
Reports for Purchase
Showing records 1 - 20 ( 27 total )
Company: Lonza Group Ag
Industry: Medical - Products
Company: Lonza Group Ag
Industry: Medical - Products
Record 2023 FDA Approvals Yet Low- End Historical Valuation
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
New FY28 Targets Provide LT Visibility to Robust Biologic Production Market
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
GLP-1 Market Update: Potential Exceeding Past Estimates, Injection vs. Oral Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Company: Lonza Group Ag
Industry: Medical - Products
CEO Change Ahead of 10/17 Capital Markets Day - Our View on CDMOs AVID, CTLT, LONN
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
1H23 Headwinds, but Record Capex Continues to Signal Growth
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Lonza Perspective for CTLT, CDMO, DHR, RGEN, SATG, STVN, TMO, WST
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Company: Lonza Group Ag
Industry: Medical - Products
1Q Update Better Than Most in Life Science - Some Sector Reads for Peers
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Upgrade to Overweight with 2023/2024 Bioprocess Outlook and 2H22 Report
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Strong 1H and Capx Spend Powerful Indicator for Bioprocess Market
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Company: Lonza Group Ag
Industry: Medical - Products
Significant Leading Indicators with Strong FY21 Earnings
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Life Science Tools: A Pivotal Upcoming Week Providing Key 2022 Read-Throughs for the Sector
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
The ''New'' Lonza Showcases Higher Growth, M&A Priorities, and Robust Tools Market
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Life Science Tools: European Perspective Suggests Better Global and Regional Outlook Than US Peers Indicate
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Company: Lonza Group Ag
Industry: Medical - Products
Aggressive Expansion Has Positive Implications for Many Life Science Companies
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Lonza Group Ag
Industry: Medical - Products
Bioproduction: Three "Nuggets" from Earnings Season - Growth, Inflection Point & Decline
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department